Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease
Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD), to announce a deal that will allow the implementation of an innovative payment model for hepatitis C treatment, part of Louisiana’s plan to eliminate the disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005539/en/
“This new model has the potential to save many lives and improve the health of our citizens. It is an important day for our state, for our partner Asegua Therapeutics, for providers, but most importantly for the patients and their families who will benefit from treatment,” said Governor Edwards. “Asegua was willing to come to the table to work with us to help Louisiana residents and we are pleased to initiate this five year partnership. Ultimately, our goal is to eliminate this disease in Louisiana, and we have taken a big step forward in that effort.”
In the United States, hepatitis C kills more people than all other infectious diseases combined. At least 39,000 people in Louisiana's Medicaid program and prison system suffer from hepatitis C infection.
“An elimination plan and innovative payment model will ensure that we can cure this deadly disease and prevent long-term illness and disability in those who have it,” said Dr. Rebekah Gee, secretary of the Louisiana Department of Health. “The Department of Health’s goal is to treat at least 31,000 people by the end of 2024 and eventually eliminate this disease.”
After extensive research and work with policy experts across the nation, the Department of Health released a solicitation of offers in January of 2019 in search of a pharmaceutical company willing to partner with Louisiana on a subscription model. Asegua Therapeutics was announced as the selected partner in April, and through subsequent discussions the parties have agreed to a modified model.
“We are pleased that Asegua has the courage to be a pioneer and chart a new path forward that will allow us to save many lives and improve the health of our citizens,” added Gee.
The innovative payment model for Louisiana addresses the needs of patients and joins the goals of both Louisiana and Asegua to extend a cure to those in need.
“This partnership will have a direct and immediate impact on the most vulnerable populations with hepatitis C – people who are on Medicaid or who receive care through the state corrections system. These populations are disproportionately affected by hepatitis C and often face the greatest difficulty in accessing care,” said Gregg Alton, Chief Patient Officer at Gilead Sciences. “We are committed to supporting efforts to eliminate hepatitis C in communities around the world and are excited to partner with the visionary leaders in Louisiana to make this public health opportunity a reality in this state.”
The innovative payment model allows the state to purchase an unlimited amount of Asegua’s direct-acting antiviral medication, the authorized generic of Epclusa® (sofosbuvir/velpatasvir) to treat patients within Louisiana’s Medicaid and Department of Corrections populations and caps the State’s medication costs.
“With this model to purchase hepatitis C medications, we can cure those within the state facilities who have this life-threatening illness and prevent the spread of the illness within our facilities,” said James LeBlanc, secretary of the Louisiana Department of Corrections. “We will also work closely with the Department of Health to implement a plan to screen and treat the local level population either while incarcerated or upon release into supervision. Most importantly, we can make sure these men and women have an opportunity to be even more successful and healthy when they return to their communities.”
The Department of Health and Asegua completed and signed a formal contract for the purchase of Asegua’s hepatitis C medication, the authorized generic of Epclusa, over five years, and for people enrolled in the Medicaid program and incarcerated people in Louisiana. The Department of Health continues to implement an elimination plan that engages partners across the state to educate the public on the availability of a cure and reach out to high-risk populations for screenings; connect people living with hepatitis C to care; expand provider capacity; and establish partnership across the state to eliminate hepatitis C in Louisiana.
About Louisiana Department of Health
The Louisiana Department of Health strives to protect and promote health statewide and to ensure access to medical, preventive and rehabilitative services for all state residents. The Louisiana Department of Health includes the Office of Public Health, Office of Aging & Adult Services, Office of Behavioral Health, Office for Citizens with Developmental Disabilities, and Healthy Louisiana (Medicaid). To learn visit www.ldh.la.gov or follow us on Twitter, Facebook, or our blog.
About Asegua Therapeutics
Asegua Therapeutics is a wholly-owned subsidiary of Gilead Sciences, Inc. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements related to Asegua Therapeutics, a subsidiary of Gilead Sciences, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties not may not realize the potential benefits of this partnership. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
ASEGUA and the ASEGUA logo are trademarks of Asegua Therapeutics LLC. EPCLUSA and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Louisiana Department of Health Contact:
Kelly Zimmerman, Media
Sung Lee, Gilead Investors
Sonia Choi, Media
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rakuten TV Launches its AVOD Service in Europe15.10.2019 08:30:00 CEST | Press release
Rakuten TV, one of the leading video-on-demand platforms in Europe, today announced the launch of its first AVOD - ad-supported video-on-demand - channels within the platform. This new business model will allow viewers to watch a wide range of content for free. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005048/en/ Rakuten TV's new UI 4.0 including "Free" section (Photo: Rakuten TV) The free section of Rakuten TV will launch with an initial offer including Hollywood and local content to be expanded to additionally include exclusive Rakuten content, TV series, documentary series, news and sport channels in the coming months - with a combined linear and on-demand offer. Among the exclusive content, Rakuten TV will present on its AVOD channel Matchday - Inside FC Barcelona, the new documentary series about FC Barcelona from the inside, offering previously unseen and exclusive scenes from the players’ private lives. Nar
Groundbreaking CloudCO Demo at Broadband World Forum 2019 Made Possible by UNH-IOL’s Role as Open Broadband Lab15.10.2019 08:00:00 CEST | Press release
The University of New Hampshire InterOperability Laboratory (UNH-IOL), an independent provider of broad-based testing and standards conformance services for the networking industry, today announced they have helped create the first publicly demonstrated lab instance of hosting the CloudCO architecture as a Broadband Forum Open Broadband Lab (OB-Lab). Working directly with industry partners BT, Swisscom, TIM, Altice Labs, DZS, Nokia, VMware, and EANTC, they will demonstrate the integration of the test platform which will be showcased at Broadband World Forum 2019 (BBWF) in Amsterdam, Netherlands this week. The intention of the OB-Labs initiative is to demonstrate an open framework for cloud-based broadband for carriers globally, and bring the promise of SDN and NFV to fruition. The demo at BBWF 2019 was built from a combination of open source from the OPNFV, ONAP, and Open Broadband Access Abstraction (OB-BAA) projects and products from Nokia, Altice Labs, DZS, and VMware. A first of it
Forter Fraud Attack Index Reveals 89% Increase In Loyalty Program Fraud15.10.2019 07:30:00 CEST | Press release
Forter, the leader in e-commerce fraud prevention, today announced the release of the seventh edition of its Fraud Attack Index. The report tracks shifting behaviors in online businesses across a variety of industries. The latest edition of the Fraud Attack Index indicates that fraud is evolving rapidly beyond the point of the transaction to accounts such as loyalty programs and abuse of return policies. Loyalty fraud increased by 89% year over year, while the total dollar amount in online fraud increased by 12% year over year. “A clear trend in online fraud is emerging,” said Michael Reitblat, CEO and Co-Founder of Forter. “The industry as a whole has done a tremendous job detecting and preventing payment fraud at the point of transaction. This eliminates the amateurs. We’re seeing fraudsters now shift their efforts earlier in the customer journey, gaining access to consumers’ accounts.” The Fraud Attack Index shows that fraudsters are having significantly more success in account take
Last Chance to Register for CES Unveiled in Amsterdam15.10.2019 07:00:00 CEST | Press release
Consumer Technology Association (CTA): WHAT: The Consumer Technology Association (CTA) ® today announced the last chance to register for the third annual CES Unveiled in Amsterdam. CES Unveiled is an official CES® 2020 preview event, bringing together executives, influential media and prominent industry influencers to experience the latest tech innovations from across Europe. Europe welcomed more than 16,000 attendees to CES 2019 and continues to lead innovation by example. CES Unveiled promotes the continued value it shares with Europe through partnerships across government, business and research. CES Unveiled in Amsterdam will focus on the theme “Tech Improving Lives,” featuring an expected 100 exhibitors (including 50+ startups) from the Netherlands and across Europe. Some top exhibitors include: Aitheon – Integrates AI and Robotics in a user-friendly way to ensure businesses become automated in a single, simple platform Crescent Tech – Provides the world’s first purpose designed we
Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD15.10.2019 06:45:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA) countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD. This is the third transaction in FY19 that furthers Takeda’s strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire. “The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” said Costa Saroukos, Chief Financial Officer, Takeda. While these products continue to play important roles in meeting patient needs, they are primarily outside of Tak
Thales Named a Market Leader in KuppingerCole Analysts Leadership Compass for Identity-as-a-Service Access Management15.10.2019 06:00:00 CEST | Press release
Thales today announced that it has been positioned as a Market Leader in the 2019 KuppingerCole Leadership Compass for Identity-as-a-Service (IDaaS) Access Management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191014005576/en/ (Photo: Thales) The report recognized Thales, through its SafeNet Trusted Access offer, as a market leader in terms of the number of customers, partner ecosystem, and global reach in the IDaaS Access Management market. KuppingerCole’s Leadership Compass takes a thorough look at the overall IDaaS Access Management industry, provides in-depth analysis of the main players in the market, and rates vendors on innovation, product features, and market reach. “With a strong global presence, SafeNet Trusted Access presents a flexible solution based on standards and, in addition, agents as a service to cater to the access management requirements of organizations with broad contextual authentication needs,”